Datatrak International Inc (OTC:DTRK)

First Quarter 2013 Results

• Revenue increased by 22% to $2.6 million in the first quarter of 2013 compared to $2.1 million in the first quarter of 2012 due to strong new contract sales which fueled backlog increases throughout 2012 and in the first quarter of 2013 as well.
• For the three months ended March 31, 2013, the Company recorded other income of $750,000. DATATRAK received $750,000 from a third-party in connection with activities and arrangements associated with its marketing and re-branding initiative related to the Company's launch of its new ticker symbol, DTRK.
• DATATRAK's backlog at March 31, 2013 was $18.8 million compared to a backlog of $17.8 million at December 31, 2012.

"The soundness of our strategy and strength of execution continue to be evidenced by our strong financial metrics, market-leading growth rates and industry recognition as a thought leader," stated Laurence P. Birch , DATATRAK's Chairman of the Board and CEO. "As the macro-economic environment begins to improve and FDA drug approvals reach record levels, clients continue to search out the benefits provided by our global cloud-based solution – reduced friction costs, real-time access to data and a single source vendor."

"Additionally, we are beginning to see expansion of the clinical trial frontier – from a large scale focus on Big Data to a micro-focus on the patient," continued Birch. "As demand for greater control of individual data fuels the digital health movement, DATATRAK is positioned to lead the charge in innovation with our Technology Driven Drug Development (TD3^™) initiative. TD3^™ provides Life Science companies with our cost effective platform to evaluate the viability of their drug pipeline and reallocate focus and resources quickly in order to capitalize on new opportunities – all in a manner that enhances patient safety – from Concept to Cure^®."

CLEVELAND, May 13, 2013 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced a new partnership with Argentinian CRO STAT Research. STAT Research provides a full range of research services in the Latin American region.

STAT Research CEO Dr. Conrado J. Estol stated: "In the context of a rapidly expanding clinical trial field in the early 2000's, we saw the opportunity to develop a company to become leaders based on our previous research expertise developed over many years in the USA. Our initial focus on CNS soon spanned into many other medical specialties and our group grew solid by incorporating some of the people with most clinical trial experience in the region. Our recent partnership with DATATRAK will add the necessary tools to achieve much more effective and efficient results in an increasingly complex and time-sensitive research environment".

"Our partnership with STAT Research combines the DATATRAK ONE™ technology with local industry experts to create a superior solution for advancing clinical trials in Latin America," stated Laurence P. Birch , DATATRAK's Chairman of the Board and CEO. "We look forward to assisting STAT Research in leveraging the DATATRAK ONE™ clinical research platform to reduce clinical trial costs and accelerate drug development timelines."

CLEVELAND, March 13, 2013 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical^™ technologies and delivering related services for the clinical trials industry, today announced its operating results for the fourth quarter and full year of 2012.

"We believe the transformative nature of the disruptive technology offered in our cloud-based DATATRAK ONE^™ software suite continues to drive efficiencies for our clients, resulting in positive financial performance for DATATRAK in 2012," stated Laurence P. Birch , DATATRAK's Chairman of the Board and CEO.  "By maintaining a laser-like focus on our customers, we have been able to generate positive cash flow allowing us to increase our investment in the DATATRAK ONE^™ platform and our other strategic initiatives---a virtuous cycle that will continue to allow our customers to enjoy what many believe to be the single most powerful eClinical platform in the industry.  We believe this disciplined investment plan has unlocked value for our clients by providing a single source vendor for their comprehensive clinical trial needs, complete with significant product releases and value-added consulting services."

Birch concluded, "It has been our experience that while many of our competitors have expensive offerings with significant hidden costs and can be monolithic in their dealings with the research professionals who are pursuing more flexible eClinical alternatives, the organizational agility and flexibility afforded by the DATATRAK ONE^™ offering empowers  more sophisticated clients to better respond to normal clinical trial ebbs and flows with nimbleness and efficiency – from ease of protocol design through trial lock, we support our clients from Concept to Cure^®."